Vidcast:  https://youtu.be/iWz4PaDr3gM

 

Two doses of the Moderna mRNA vaccine prevent 100% of CoVid infections in adolescents 12 to 18 years of age.  The company just announced the results of its phase 1-2 study in preparation for submission to the FDA in June seeking an Emergency Use Authorization.

 

A total of 3,732 teens were randomized 2 to 1 to receive the vaccine.  CoVid infection prevention efficiency was 93% two or more weeks after even the first dose.  The side effects of the vaccine were mild to moderate in severity and comparable to those seen in adults.

 

Moderna and Pfizer are both conducting vaccine trials with infants, toddlers, and younger children using a range of test doses.

 

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine/

 

#moderna #CoVid #vaccine #teens #adolescents